Neptune Biotech: Announcement on the Implementation of Other Risk Warnings and Trading Suspension and Resumption of the Company’s Stocks
Securities code: 000078 Securities abbreviation: Neptune Biotechnology Announcement number: 2026-027
Shenzhen Neptune Bioengineering Co., Ltd.
Announcement on the Implementation of Other Risk Warnings and Trading Suspension and Resumption of Trading of the Company’s Stocks
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
Grant Thornton Accounting Firm (Special General Partnership) (hereinafter referred to as "Grant Thornton Accounting Firm") issued an internal control audit report with a negative opinion on the 2025 internal control of Shenzhen Neptune Bioengineering Co., Ltd. (hereinafter referred to as the "Company" or the "Company"). According to Article 9.8.1 (4) of the "Shenzhen Stock Exchange Stock Listing Rules (Revised in 2026)", if a listed company issues an audit report with no opinion or negative opinion on the internal control of the financial report in the most recent fiscal year, or fails to disclose the internal control audit report of the financial report in accordance with regulations, the Shenzhen Stock Exchange will implement other risk warnings on the company's stocks.
The company's shares will be suspended for one day from the market opening on April 30, 2026 (Thursday), and will resume trading from the market opening on May 6, 2026 (Wednesday).
The company's stock will be subject to other risk warnings from the opening of the market on May 6, 2026 (Wednesday). The stock abbreviation will be changed from "Neptune Bio" to "ST Neptune"; the stock code will remain unchanged, still "000078"; the stock trading day increase or decrease is limited to 5%.
1. Stock type abbreviation, stock code and the starting date of other risk warnings
Stock type: RMB ordinary shares A shares
Stock abbreviation: changed from "Neptune Bio" to "ST Neptune"
Stock code: 000078
The starting date for implementing other risk warnings: May 6, 2026
The company's stock trading suspension and resumption starting date: trading will be suspended for one day from the market opening on April 30, 2026 (Thursday), and trading will be resumed from the market opening on May 6, 2026 (Wednesday).
After the implementation of other risk warnings, the daily price limit for company stock trading will be changed from 10% to 5%.
2. Reasons why the company was issued other risk warnings
Grant Thornton Accounting Firm issued an internal control audit report with a negative opinion on the company's internal control in 2025. According to Article 9.8.1 of the "Shenzhen Stock Exchange Stock Listing Rules (Revised in 2026)", if a listed company issues an audit report with a disclaimer or negative opinion on the internal control of the financial report in the most recent fiscal year, or fails to disclose the internal control audit report of the financial report in accordance with regulations, the Shenzhen Stock Exchange will implement other risk warnings on the company's stocks. Therefore, the company's stocks will be subject to other risk warnings, but they will not trigger forced delisting for major violations stipulated in Section 5 of Chapter 9 of the "Stock Listing Rules".
3. Opinions and main measures of the company’s board of directors on striving to cancel other risk warnings
The company's board of directors, in a highly responsible attitude towards all shareholders, will continue to urge the company's management to actively take effective measures to eliminate the impact of relevant matters on the company as soon as possible, and strive to cancel other risk warnings as soon as possible in accordance with regulatory requirements.
According to Article 9.8.7 of the "Shenzhen Stock Exchange Stock Listing Rules (Revised in 2026)": "If a company has completed the rectification of internal control defects and the internal control can operate effectively, and applies to the Exchange to cancel other risk warnings for its stock transactions, it shall disclose the unqualified internal control audit report issued by the accounting firm on its financial accounting report for the most recent fiscal year."
In response to the deficiencies involved in the internal control audit report, the company's internal control department proactively discovered during daily supervision and inspection that the company had borrowed funds from unrelated third parties during the reporting period. It issued a special internal rectification report on this matter and required relevant departments to make rectifications within a time limit. The principal of the above-mentioned loans has been fully recovered in October 2025 and March 2026, and the pledge guarantee has been released. The company has completed the ratification procedure and convened the seventh meeting of the tenth board of directors on April 28, 2026, which reviewed and approved the "Proposal on Ratifying External Financial Aid and Guarantees" and disclosed the "Announcement on Ratifying External Financial Aid and Guarantees" on April 30, 2026, which will be submitted to the company's shareholders' meeting for review. In response to the management responsibility issues exposed by this incident, the company will initiate internal accountability to further consolidate management responsibilities. The company is promoting the revision and improvement of financial assistance, financing and guarantee management systems to plug system loopholes from the source. In the future, the company will optimize the information transmission and reporting mechanism for major matters, strengthen internal control management, information disclosure and key node approval management, improve the risk warning system, and effectively prevent similar problems from happening again. At the same time, the company will organize the finance department, finance department, board of directors office and other departments to carry out compliance training, focusing on learning the laws and regulations on standardized operations of listed companies, information disclosure and other aspects of the company's internal management system, strengthening the understanding of rules and the ability to judge business essence, and improving the awareness of standardized operations among all employees.
To apply to cancel this other risk warning, you must also satisfy that the company has completed rectification work on the matters involved. The company will apply to the Shenzhen Stock Exchange to cancel other risk warnings as soon as the conditions are met.
The company’s board of directors sincerely apologizes to the investors for this matter, and will continue to urge the company’s management to strengthen management measures, further improve the internal control management system, establish and improve the internal supervision mechanism, continuously strengthen the construction and supervision of the company’s internal control system, and ensure that the company maintains effective internal control in all major aspects.
As of the disclosure date of this announcement, the company's various production and operation activities are carried out in a normal and orderly manner. The company and relevant personnel will carefully learn from experience and lessons, strengthen the standardization of internal governance, improve the quality of information disclosure, strictly abide by relevant laws and regulations, perform information disclosure obligations in a true, accurate, complete, timely and fair manner, and safeguard the interests of the company and investors.
4. Risk reminder that may be subject to delisting risk warning
The company's 2025 internal control audit agency, Grant Thornton Accounting Firm, issued an internal control audit report with a negative opinion on the effectiveness of the company's internal control over the financial report on December 31, 2025. The above-mentioned internal control audit report with a negative opinion is an audit report that issued a negative opinion on the internal control of the company's financial report for the first fiscal year. If a listed company encounters this situation, according to the provisions of Article 9.4.4 (5) of the "Shenzhen Stock Exchange Stock Listing Rules (2026 Revision)", it should immediately disclose the risk warning that the stock transaction may be subject to a delisting risk warning.
5. The main ways for companies to receive investor consultations
During the period when the company's stock trading is subject to other risk warnings, it will accept inquiries from investors through telephone, email, interactive transactions, etc., and will respond to investors' inquiries in a timely manner without violating relevant regulations on the confidentiality of inside information. The company contact information is as follows:
Contact department: Office of the Board of Directors
Contact number: 0755-26980336
Contact email: [email protected]
Contact address: 24th Floor, Neptune Galaxy Technology Building, No. 1 Keji Zhongsan Road, Nanshan District, Shenzhen
The company reminds investors that the company's designated information disclosure media are China Securities Journal, Securities Times, Shanghai Securities News, Securities Daily and Juchao Information Network. All company information is subject to announcements published in the above designated media. Investors are advised to pay attention to the company's subsequent announcements and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shenzhen Neptune Bioengineering Co., Ltd.
April 29, 2026